Akero Therapeutics, Inc. — Net Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/5beeaaa9-cbf9-4fb8-be63-78a7aa97ea82/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-252.1M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-029514 |
| FY 2023 | $-151.8M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-022644 |
| FY 2022 | $-112.0M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-008566 |
| FY 2021 | $-100.8M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-002052 |
| FY 2020 | $-79.2M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-003043 |
| FY 2019 | $-43.8M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-002798 |
| FY 2018 | $-81.7M | 2018-01-01 – 2018-12-31 | evidence 0001558370-20-002798 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).